Laura M.
Bickley
a,
Eric
Da Silva
b,
David R.
Chettle
a and
Fiona E.
McNeill
*a
aDepartment of Physics and Astronomy, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4M1, Canada. E-mail: fmcneill@mcmaster.ca
bDepartment of Physics, Toronto Metropolitan University, 350 Victoria Street, Toronto, ON M5B 2K3, Canada
First published on 5th March 2025
High levels of strontium can cause impaired bone growth in children, and excess mortality in animals, but at low doses there are no known toxic effects in humans. Strontium is purported to be beneficial for post-menopausal bone density loss and strontium citrate is used as a nutritional supplement by some women. This article describes development of a system to monitor bone strontium levels quickly and accurately for use in the health risk assessment of self-administered strontium supplements. Previous radioisotope-based strontium measurements take up to 30 minutes for measurements and are not portable. The new system is comprised of a silicon drift detector (SDD) with a 109Cd source in a 180° backscatter geometry. Novel anthropomorphic phantoms were developed for system calibration from 3D printed PLA shells with strontium-doped hydroxyapatite cores. The system performance was investigated using two sources of different reported activity. During development, it was noted that while one 109Cd source did emit an order of magnitude higher 88 keV γ-rays than the other, it did not emit an order of magnitude greater fluence of silver X-rays. This is attributed to differences in source encapsulation. This lower-than-expected X-ray fluence meant that the best minimum detectable limit (MDL) was determined to be 22 μg Sr per g Ca for a 30 minutes measurement. However, low system dead times indicated that the system was not used at maximum throughput, and it is predicted that with higher fluence silver X-ray sources, the system could achieve a minimum detectable limit of 7 μg Sr per g Ca.
Later studies were performed on strontium ranelate, a drug initially approved for osteoporosis treatment in the European Union in 2004 (as Protelos®8) and Australia in 2007 (as Protos®9). Four large-scale clinical trials (named PREVOS,10 STRATOS,11 TROPOS12 and SOTI13) aimed to investigate the required minimum dose for beneficial effects (PREVOS, STRATOS), and the long-term efficacy and safety of the drug (TROPOS, SOTI). These studies were able to show a clear relationship between strontium ranelate supplementation and BMD. For participants in the SOTI study, those receiving a dose of strontium ranelate of 2 g per day had a 6.8% increase in BMD averaged across three different bone sites, compared with a 1.3% decrease below the original baseline level for the placebo group.13 Similar results were seen in the TROPOS study12 which showed a significant increase in the BMD of women who took 2 g per day of strontium ranelate as compared with women in a placebo group. This study also showed a decrease in the number of new vertebral fractures in women receiving strontium supplementation.12Post hoc studies14,15 on the SOTI and TROPOS groups14 showed that for every 1% increase in BMD beyond year one, the relative risk of a new vertebral fracture dropped by an average of 3%. Rather than a single dose of 2 g per day strontium ranelate, participants in the PREVOS and STRATOS studies16 were given a range of doses of strontium ranelate: 125 mg per day, 500 mg per day, 1 g per day or 2 g per day. The participants showing the largest increase in BMD from the original baseline were those in the 2 g per day group, with no significant effects being noted below a dose of 1 g per day. These studies also showed an increase in markers of bone formation, with levels in the 2 g per day group being significantly higher than those in the placebo group. The BMD values reported by these studies may be inflated, as studies17,18 showed an overestimation of the BMD by 10% for every 1% increase in strontium concentration (i.e., the ratio of Sr/(Sr + Ca)) in bone. This should be considered when analyzing the efficacy of supplementation.
Mild side effects were reported in these studies which included diarrhea and gastritis, although these particular studies13–16 did not report any adverse events. However, a review by the European Medicines Agency (EMA)19 found that those who suffered from heart disease, venous thromboembolic events, peripheral artery disease or cerebrovascular disease were at increased risk of heart attack from strontium ranelate use, and for this reason the use of the drug is now restricted in Europe. Australia20 followed suit, restricting use of the drug in 2014.
Strontium ranelate was never approved for use in Canada, and so there are no populations of women who were prescribed the drug. However, there are Canadian women who choose to supplement their diet with strontium in the belief that it prevents or treats osteoporosis.21,22 Compounds such as strontium citrate are available from health food stores. Canada recognizes that there may be health risks associated with strontium supplementation23,24 and requires businesses selling supplements containing more than 4 mg strontium to attach a warning label about cardiovascular risks. Canada has also legislated a limit of strontium in drinking water of 7 mg per L per day.25 To date, no known rigorous studies have been done on the long-term health effects of strontium citrate ingestion. A study in rodents found that strontium citrate increased the concentration of strontium in bone by a factor of 1.5 after 8 weeks.26 Pilot studies showed that women who reported self-supplementing with strontium citrate had increasing strontium levels in bone and were often ingesting more than 100 times the daily recommended limit of strontium.21,22 There are therefore potential populations of people in Canada who have elevated exposure to strontium, but the impact on their health is not known. Studies that compare a measured bone strontium level with the potential health risks would provide information regarding risk, allowing government to make informed decisions about the sale of these supplements.
Such studies require a method of assessing bone strontium non-invasively in vivo. Early work on the quantification of bone strontium in vivo was performed via animal studies27,28 using X-ray fluorescence (XRF). Both of these early systems utilized a Si(Li) detector, and either a 109Cd or 125I X- and γ-ray source.27,28 No further work was conducted on these systems beyond the initial publications, but in 2004 the technology was re-examined,29 utilizing a Si(Li) detector, a 109Cd source, 1800 s live-time measurements, and plaster of Paris (poP) phantoms. A 90° geometry was found to produce a better signal-to-noise ratio when compared to a 180° backscatter geometry. This system produced phantom based minimum detectable limits (MDL) ranging from 110 μg Sr per g Ca for low-purity phantoms to 170 μg Sr per g Ca for high purity phantoms. A re-design of the collimator in 2006 (ref. 30) further improved the MDL of the system to (44.6 ± 0.9) μg Sr per g Ca. The same Si(Li) detector was employed, but with a 125I source, 1800 s live time measurements, and a 180° backscatter geometry, as the 180° geometry was easier to setup compared to the 90° geometry.30 This MDL was further reported as being improved in 2007 to (22.9 ± 0.6) μg Sr per g Ca while using the same 1800 s live-time, geometry, detector and source and the system was applied in in vivo studies to measure baseline Sr levels in 22 non-supplementing subjects.31 This same system was then used in 2008 (ref. 32) to measure strontium in tooth enamel (MDL 28 μg Sr per g Ca, measurement time 1000 s), and in 2012 (ref. 33) to measure strontium levels in human cadaver fingers [MDL (22.9 ± 0.6) μg Sr per g Ca,34 measurement time 1800 s]. A further study used the system to investigate the difference in strontium concentrations in rats following ingestion of strontium ranelate versus strontium citrate26 in 2013 although no updated MDL was reported for these rat studies. Finally, two pilot studies in 2012 (ref. 21) and 2014 (ref. 22) reported using the same system, each with an MDL of 21–23 μg Sr per g Ca35 in phantoms, to measure the concentration of strontium in bone of volunteers who had been self-supplementing with strontium citrate. No in vivo MDL was able to be reported due to inherent strontium contamination of the phantoms. Other research groups developed similar systems to measure concentrations of strontium in bone,36,37 and one study in 2017 (ref. 36) investigated the concentration of strontium in the bones of a population of children in China who had been exposed to lead.
Much of the research described above employed a measurement time of 1800 s live time. This is possibly too long for a useful clinical tool. Some groups therefore tested shorter measurements times, varying from 1 s to 1000 s.32,33,36–39 Researchers in these two studies36,37 were able to employ short detection times because they used an SDD detector in an X-ray tube based handheld system, that is a portable (p)XRF device. A study in human teeth7 used shorter detection times but this does not directly translate to an indication of the required time for measurements in bone, and a study38 aiming to develop a correction technique for soft tissue overlay was able to test the theory without a long measurement time. While most measurements in the literature are reported in terms of true times, this does not necessarily explain the clinical utility accurately. Dead times for these systems ranged from as low as 15% (ref. 21) to as high as 50%,22 leading to actual (true or clock) measurement times of 2100 s to 2700 s. While a 40 minutes measurement is acceptable for in vitro studies, and experimental in vivo measurements, if this technology is to be translated to application outside of the laboratory, especially as a point-of-care device, then the total time of measurement should be on the same order of magnitude as other clinical procedures, such as a DXA scan. DXA scans are employed to test the BMD of a patient over multiple bone sites in the body.40 They typically take on the order of 5 to 20 minutes41 in total for multiple site measurement.
This work aimed at developing an improved XRF-based in vivo bone strontium measurement system that could attain the required detection limits at measurement times that approach those of other point-of-care devices. We describe the development of an SDD based system employing a 109Cd source, calibrated using a set of 3D printed anthropomorphic finger calibration phantoms. We discuss the accuracy of a soft tissue correction factor and show how these phantoms may create a simpler measurement system that being portable may be able to be deployed in a clinical setting.
A source holder and detector cap that had been previously designed for in vivo measurements of iron in skin42 was used for measurements of strontium in bone. This combination of a collimator, source holder and cap was made from aluminum with a 250 μm thick styrene window while the source holder was made of tantalum.
Two different source activities were used in this study. The sources were presumed to be identical in design having been made in the same facility: the 109Cd was plated onto a 1 mm diameter circular 30 μm thick Ag plug and placed in a 3 mm × 3 mm steel capsule, with a 100 μm thick titanium entrance window. We identify this source as Source 1 which had a nominal activity of 79.82 MBq in April 2023 (down from 5.59 GBq in February 2016, calculated), while the source we identify as Source 2 had a nominal activity of 1.16 GBq in April of 2023 (down from 4.995 GBq in August 2020, calculated).
The calcium hydroxyapatite infill was created by adding calcium hydroxide to calcium hydrogen phosphate dibasic to achieve a Ca/P ratio of 1.67. A strontium standard solution, in the form of an ICP-OES standard solution (10000 μg Sr per L, Ultra Scientific) was then added to reach the desired concentration. Phantoms of strontium concentration 0, 25, 50, 100, 250, 500, 750, 1000, 1250, 1500 μg Sr per g Ca were created. The components were thoroughly mixed to ensure a homogenous distribution of strontium. A setting solution of sodium phosphate dibasic (Sigma-Aldrich) was then added until a free-flowing consistency was achieved, and the mixture was poured into the 3D printed phantom shells and left to set for a week. To minimize air bubbles the shells were tapped firmly on a hard surface immediately after filling to remove any air bubbles.
A phantom with no soft tissue (hereafter referred to as a 0 mm phantom) was modelled as a cylinder with length of 60 mm and diameter 7.5 mm. These were created from a cylindrical mould with wall thickness of 2.0 mm.
The attenuation coefficient of the 3D printed plastic was measured to ensure it was a suitable soft tissue model for this X-ray energy range. While the coefficient could be calculated from the presumed composition, other studies44 have suggested that the attenuation coefficient can vary from manufacturer to manufacturer, so empirical testing is required. A custom source holder was printed for the 109Cd source, with a lead pinhole collimator. Previously printed45 bricks of 100% infill PLA plastic with varying thicknesses (up to a total distance of 10 cm) were placed between the source and the detector and spectra acquired for 5 minutes.
The attenuation was calculated by plotting the area of the two Ag K X-ray peaks at 22.2 keV and 24.9 keV against the PLA thickness. An exponential function was fitted using Origin 2023 and the attenuation coefficients for 22.2 and 24.9 keV were calculated. These were then compared to the theoretical coefficients for soft tissue at these energies.
Phantoms were each measured for 5 minutes and 30 minutes live time for each source resulting in a total of 4 sets of calibration measurements. The 0 μg Sr per g Ca hydroxyapatite phantoms for each tissue overlay thickness were measured 5 times, while all other hydroxyapatite phantoms were measured 3 times for each source. Between measurements each phantom was removed and replaced for the next measurement.
Peak fitting was performed using Origin 2023. A mathematical model was fitted to the spectra to extract X-ray peak areas and the Levenberg–Marquardt method of analysis was used to find the best fit. A sample spectrum from a 1500 μg Sr per g Ca strontium phantom is shown in Fig. 2. Strontium Kα and Kβ X-rays and features from Compton and coherently scattered Ag X-rays (22.2 keV and 24.9 keV) are clearly observed, as is an X-ray signal from nickel in the detector.
The 14.1 keV Sr Kα X-ray, the Ni Kα X-ray, and the 22.2 keV and 24.9 keV coherently scattered Ag K X-rays from the 109Cd decay were fitted using a Gaussian function with a linear background model (eqn (1) below). The 15.9 keV strontium Kβ X-rays were fitted using two linked Gaussian functions on a linear background model (eqn (2) below). The Compton scatter distribution from the Ag X-rays were fitted using a Voigt function given by OriginPro 2023 on top of a complementary error function background model (eqn (3)–(5) below).
![]() | (1) |
![]() | (2) |
![]() | (3) |
![]() | (4) |
![]() | (5) |
Net peak areas for the strontium Kα and Kβ X-rays were plotted against phantom concentration for each tissue overlay thickness to obtain calibration lines for each finger phantom tissue overlay thickness. The MDL for each phantom thickness set was then calculated as twice the uncertainty in the zero-concentration phantom divided by the slope of the appropriate calibration line to obtain the detection limit in units of μg Sr per g Ca.
Strontium is a ubiquitous contaminant in calcium compounds and there is often an observed non-zero calibration line intercept arising from strontium in the phantom materials. The strontium concentration of potential phantom contamination was calculated by dividing the intercept of the calibration line by the slope of the given calibration line. This assumes the intercept on the calibration line arises solely from contamination and that the spectral fitting function does not introduce an artifact.
Fig. 4 shows the sensitivity of the system i.e. the measured Kα and Kβ peak area counts per μg Sr per g Ca for both sources and both times. As expected, the sensitivity decreased with increasing finger phantom soft tissue thickness. Source 2 is reported by the manufacturer as being a factor of 10 times more active than Source 1. However, for the 5 minutes counts and the 30 minutes counts, the sensitivity was found to be only 25% and 10% higher, respectively.
Fig. 5 shows the MDL as determined from the Kα calibration line versus phantom wall thickness for both sources for 5 minutes and 30 minutes, respectively. As expected, the MDL becomes poorer with increasing phantom wall thickness. Only the Kα detection limit is shown. The Kβ detection limit was calculated but was significantly poorer than the Kα detection limit in every instance. Overall, when the Kα and Kβ MDLs were combined, (using an inverse variance weighted mean), it was found that the addition of the Kβ information only improved the detection limit by (1.0 ± 0.2)% on average. As so little extra information was provided, further analysis focused solely on the Kα calibration slope. Table 1 shows the MDLs for the thinnest and thickest phantoms for both sources for both time intervals. The relationship between the 5 minutes and 30 minutes MDLs for each source were found to be close to the expected value of 0.41 (from 1/√6). The ratio of the 30 minutes MDL to the 5 minutes MDL for Source 1 was 0.40 ± 0.03 while the ratio for Source 2 was 0.43 ± 0.03.
Source | Time (s) | MDL (μg Sr per g Ca) 0 mm thickness | MDL (μg Sr per g Ca) 4 mm thickness |
---|---|---|---|
Source 1 | 300 | 60 | 110 |
Source 2 | 300 | 45 | 136 |
Source 1 | 1800 | 29 | 46 |
Source 2 | 1800 | 22 | 52 |
Source | Mean Sr contamination (mg Sr per g Ca) | IVWM Sr contamination (mg Sr per g Ca) |
---|---|---|
Source 1 5 minutes | 0.92 ± 0.03 | 0.86 ± 0.03 |
Source 1 30 minutes | 0.87 ± 0.1 | 0.77 ± 0.03 |
Source 2 5 minutes | 0.79 ± 0.03 | 0.76 ± 0.03 |
Source 2 30 minutes | 0.85 ± 0.04 | 0.82 ± 0.03 |
Average | 0.86 ± 0.03 | 0.80 ± 0.01 |
Slope | R 2 of correlation | P-Value correlation | Z-Score (difference of slope from 1) | P-Value (two-tailed test) for Z score | |
---|---|---|---|---|---|
Source 1 5 min | 0.99 ± 0.10 | 0.957 | 0.00245 | −0.11 | 0.912 |
Source 1 30 min | 0.93 ± 0.07 | 0.976 | 0.00104 | −1.00 | 0.353 |
Source 2 5 min | 1.20 ± 0.12 | 0.958 | 0.00238 | 1.64 | 0.230 |
Source 2 30 min | 1.14 ± 0.08 | 0.979 | 8.45 × 10−4 | 1.71 | 0.087 |
Mean slope estimate | 1.07 ± 0.09 | N/A | N/A | 0.780 | 0.435 |
The R2 and p-values values for the strontium Kα calibration lines for both sources and both measurement times and the R2 and p-values for the calibration lines with the strontium Kα X-ray signal normalized to the nickel Kα X-ray signal were examined. If we assume that the removal and replacement of phantoms between measurements could result in variation of position, then a successful normalization method should improve the linearity of the calibration lines. R2 and p-values of all calibrations found that any improvement in linearity of the calibration line as a consequence of the normalization were negligible. Only 2 out of 24 Ni Kα/Sr Kα calibration lines showed improvement over the Kα X-ray signal calibration lines alone, with R2 values improving from 0.80 to 0.84, and 0.96 to 0.97, and p-values improving from <0.0003 to <0.0002.
Fluorescing source | Acquisition time (s) | MDL (μg Sr per g Ca) | |
---|---|---|---|
Pejovic-Milic et al. 2004 (ref. 29) | 109Cd | 1800 | 250 (finger, in vivo) |
560 (tibia, in vivo) | |||
110 (low purity phantom) | |||
170 (high purity phantom) | |||
Zamburlini et al. 2006 (ref. 30) | 125I | 1800 | 44.6 (phantom) |
Zamburlini et al. 2007 (ref. 31) | 125I | 1800 | 22.9 (finger phantom) |
Heirwegh et al. 2012 (ref. 33) | 125I | 1800 or 3600 | 22.9 (ex vivo finger)18 |
Moise et al. 2012 (ref. 21) and Moise et al. 2014 (ref. 22) | 125I | 1800 | 21–23 (phantom)26 |
Specht et al. 2017 (ref. 36) | PXRF | 120 | 1.3 (no soft-tissue equivalent) |
14.5 (9 mm thickness soft-tissue equivalent) | |||
Zhang et al. 2022 (ref. 37) | PXRF | 120, 180, 300 | 5.2 (5 mm thickness soft-tissue equivalent) |
This work Source 1 | 109Cd | 300 | 60 (0 mm) and 111 (4 mm) |
This work Source 2 | 109Cd | 300 | 45 (0 mm) 136(4 mm) |
This work Source 1 | 109Cd | 1800 | 29 (0 mm) and 46 (4 mm) |
This work Source 2 | 109Cd | 1800 | 22 (0 mm) and 52 (4 mm) |
The use of an SDD was expected to attain a lower detection limit through the faster processing ability of this type of detector. However, the dead times in this 109Cd system were low, in the range from 4–5%. This system did not achieve input count rates where the SDD, despite having a smaller detector surface area, could have an advantage over a Si(Li) detector. There is therefore an opportunity for improved detection limits if a source with significantly higher Ag X-ray fluence rates could be used.
The use of Source 2, a reportedly significantly higher activity 109Cd source (as assessed from the 88 keV signal strength), was expected to result in an approximate factor of 10 greater Ag X-ray fluence, and thus a factor of 3 improvement in the MDL. The MDL was thus expected to be of the order of 15 μg Sr per g Ca for a 300 s counting time and 7 μg Sr per g Ca for an 1800 s counting time. This would have been a marked improvement over the previous radioisotope-based system. This was not observed in practice. Strontium Kα X-ray signal sensitivities were only a factor of 1.8 higher for Source 2 as compared to Source 1.
Comparison of the spectra for the same phantom for the two different sources determined that the relative heights of the silver 22 keV and 24.9 keV X-rays were different between the sources. In addition, the relative size of the background above 25 keV was significantly higher in Source 2. Direct measurements of each source were made through a pinhole collimator, and it was observed that the relative heights of the 88 keV, 24.9 keV and 22 keV peaks were different (Fig. 6). This change in relative height is likely a result of differential attenuation, and so we hypothesize that the source encapsulation was slightly different. Using the changes between the 22 keV and 24.9 keV photons we estimate that source 2 has a thicker capsule that would crudely equate to approximately a 200 μm greater thickness of steel.
The small improvement in MDL with Source 2 is unexpected; however, an estimate of the MDL can be made for a higher activity source of the encapsulation type of Source 1. When Source 1 was purchased, it was a factor of 70 higher in activity than when measurements were performed. However, a 70 times greater Ag X-ray fluence would create too high a dead time to make measurements feasible. Simple calculations using a paralyzable deadtime model suggest that a source of encapsulation type 1 that is 16 times higher in activity would result in a deadtime in this system of 40 to 50%, however this could be further reduced with faster electronics. This suggests that the system could attain a MDL of 7 μg Sr per g Ca using a source of that encapsulation type for an 1800 s live time measurement, which would be a significant improvement over other radioisotope-based systems.
This MDL approaches the performance of hand-held X-ray set based systems, which use 22.2 keV Ag X-rays. While the handheld X-ray systems would still have better performance, likely due to higher incident X-ray fluence, there can be regulatory challenges (such as handheld X-ray systems being regulated by a different governing body than radioisotopes) to their use in human studies in some jurisdictions e.g. Ontario, Canada. For those jurisdictions, this 109Cd-based SDD system would offer advantages of a better MDL than prior radioisotope systems, that is close to that of handheld X-ray systems, and attainable in a 5 minutes live counting time (10 minutes true counting time) measurement, if higher activity sources could be obtained. In addition, the doses delivered by these systems are extremely high, delivering 21 mSv to a 1 cm2 area of skin in 120 s,36 as opposed to our system which delivers 1.1 mSv to 0.8 cm2 of skin.42 The dose for handheld XRF systems can be reduced, but at the cost of an increase in the MDL. There are no regulatory dose limits for this type of medical device in Ontario, but the occupational/environmental regulatory limit set for doses to the skin in Canada for a member of the public is 50 mSv per year over a 1 cm2 area,46 meaning that any handheld system would deliver 42% of this maximum annual dose permitted for a member of the public.
Previous studies determined levels of contamination for plaster of Paris phantoms of 363 μg Sr per g Ca,35 while for the strontium doped calcium hydroxyapatite phantoms in this study, the level of contamination was determined to be (0.86 ± 0.03 mg Sr per g Ca), almost 3 times greater. This is unfortunate as it was hoped that the creation of hydroxyapatite phantoms would result in lower contamination levels as was found to be the case for calcium hydroxyapatite phantoms reported in 2008.32 We hypothesize that the contamination difference is likely due to contamination of the reagents, as it was reported in 2008 (ref. 32) that one of the reagents (CaCO3) had an inherent strontium contamination of approximately 420 μg Sr per g Ca, leading to a phantom containing 370 μg Sr per g Ca. Those researchers were able to purify the CaCO3 reducing the contamination of the resulting phantom to 2 μg Sr per g Ca. We therefore suggest that future phantoms source appropriate reagents and purify the materials before use.
However, this normalization may still be useful for in vivo work. While it is straightforward to ensure a phantom is measured in the same position relative to the detector face in repeated measurements, this will not be possible with human participants. More importantly, with measurement times ranging from 120 s (ref. 36 and 37) to 1800 s (ref. 21, 22, 29, 30, 31 and 33) live times, there is potential for participants to move during the measurement. Any restraints would be required to be minimal and so participant motion is possible. A normalization that could help reduce the variation in the data would be advantageous and this should be explored in future work.
Calibration against 3D printed PLA plastic phantoms suggests that the system can employ a Compton estimation method and thus the system would require no ultrasound measurements to be performed. This, in combination with the portability of the system, offers advantages over prior radioisotope-based systems. However, challenges with Sr contamination in phantom materials and the lack of a normalisation method to account for patient motion mean that further work is required. Finally, this is a phantom based study and physiological factors, such as the potential for contamination due to strontium excreted in sweat,47 will need to be taken into account before the system can be tested in human studies.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4ja00464g |
This journal is © The Royal Society of Chemistry 2025 |